١	١	R	С	F	О	R	М	3	7	4
---	---	---	---	---	---	---	---	---	---	---

## U.S. NUCLEAR REGULATORY COMMISSION

PAGE	1	OF	4	_ PAGES
	Ame	ndme	nt No	. 17

## **MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with e-mail dated April 23, 2014
Cassia Regional Medical Center	3. License Number 11-27393-01 is amended in
* D	its entirety to read as follows:
2. 1501 Hiland Avenue	4. Expiration date August 31, 2018
Burley, Idaho 83318	5. Docket Number: 030-32333
1	Reference Number:
Byproduct, source, and/or special     nuclear material     7. Chemical and	Vor physical form  8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. As needed
B. Any byproduct material B. Any permitted by 10 CFR 35.200	B. As needed
9. Authorized use:	5

## CONDITIONS

- 10. Licensed material may be used or stored only at the licensee's facilities located at 1501 Hiland, Burley, Idaho.
- 11. The Radiation Safety Officer (RSO) for this license is Lisa M. Bosworth.
- 12. Licensed material is only authorized for use by, or under the supervision of:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

B. Any imaging and localization study permitted by 10 CFR 35.200.

A. Individuals permitted to work as an authorized user, authorized nuclear pharmacist, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE	2	of	4	PAGES
		License Number 11-27393-01					
	MATERIALS LICENSE SUPPLEMENTARY SHEET	Docket or Reference Number 030-32333					
		Amendment No. 17					

B. The following individuals are authorized users for the material and medical uses indicated:

<u>Authorized Users</u>	Material and Use
Duane D. Blatter, M.D.	35.100, 35.200
R. Thomas Bonk, M.D.	35.100, 35.200
John K. Dedic, M.D.	35.100, 35.200
Margaret F. Ensign, M.D.	35.100, 35.200
V. Frank Gabor, M.D.	35.100, 35.200
Jerry E. Handy, M.D.	35.100, 35.200
William J. Halden, M.D	35.100, 35.200
David C. Hardy, M.D.	35.100, 35.200
Colleen Harker, M.D.	35.100, 35.200
Dale P. Harris, M.D.	35.100, 35.200
John N. Henrie, M.D.	35.100, 35.200
Stephen T. Hunt, M.D.	35.10 <mark>0, 35.20</mark> 0
John M. Jacobs, M.D.	35.100, 35.200
Patrick R. Luers, M.D.	35.100, 35.200
Timothy J. Micklos, M.D.	35.1 <mark>00, 35.</mark> 200
W. James Morrison, M.D.	35.100, 35.200
David Pisanl, M.D.	35.100, 35.200
Jack Rampton, M.D.	35.100, 35.200
Ronald Ruff, M.D.	35.100, 35.200
Clark L. Searle, M.D.	35.100, 35.200
Steven L. Souza, M.D.	35.100, 35.200
Robert T. Troxell, M.D.	35.100, 35.200
Dennis M. Welch, M.D.	35.100, 35.200
Frederick B. Fitts, Jr., M.D.	35.100, 35.200
Erice S. Anding, M.D.	35.200
William Marcus Brann, M.D.	35.200
J. Lee Burke, M.D.	35.200
Thomas R. Calame, M.D.	35.200
Brian Crandall, M.D.	35.200
Thomas Stonestreet Edwards II, M.D.	35.200
Edward W. Ganelion, M.D.	35.200
Steven C. Horton, M.D.	35.200

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE	3	of	4	PAGES
		License Number 11-27393-01					
	MATERIALS LICENSE SUPPLEMENTARY SHEET	Docket or Reference Number 030-32333					
		Amendment No. 17					

Authorized Users	Material and Use
Howard R. Lee, M.D.	35.200
Robert William Mackie Jr., M.D.	35.200
J. Joseph Perry, M.D.	35.200
James Revenaugh, M.D.	35.200
Sherman Sorenson, M.D.	35.200
Gary P. Symkoviak, M.D.	35.200
Konstantyn Y. Szwajkun, M.D.	35.200
Imran Zubair, M.D.	35.200
Spencer J. Robertson, M.D.	35.100; 35.200
Control of the Contro	

- 13. The licensee shall conduct a physical inventory every 6 months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sources and/or devices received and possessed under the license. Records of inventories shall be maintained for 3 years from the date of each inventory and shall include the radionuclides, quantities, manufacturer's name and model numbers, and the date of the inventory.
- 14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing financial assurance for decommissioning.
- 15. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE	4	of	4	PAGES
		License Number 11-27393-01					
	MATERIALS LICENSE SUPPLEMENTARY SHEET	Docket or Reference Number 030-32333					
		Amendment No. 17					

16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

OP PEO

A. Application dated May 28, 2008	(ML081720161)
B. Letter dated May 21, 2012	(ML12165A632)
C. Letter dated July 19, 2012	(ML12205A185)
D. Letter dated December 10, 2013	(ML13361A075)
E. Letter dated January 31, 2014 with enclosures	(ML14057A682)
F. E-mail dated April 23, 2014	(ML14153A618)

TATE OSTATE OF STATE OF STATE

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

/RA/
Date June 19, 2014 By \_\_\_\_\_

Jacqueline D. Cook, Senior Health Physicist Nuclear Materials Safety Branch B Region IV Arlington, Texas 76011-4511